Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Buy
69
PBH Quote, Financials, Valuation and Earnings
Last price:
$84.22
Seasonality move
:
5.86%
Day range:
$83.08 - $84.37
52-week range:
$62.35 - $90.04
Dividend yield:
0%
P/E ratio:
19.76x
P/S ratio:
3.78x
P/B ratio:
2.34x
Volume:
205K
Avg. volume:
357.5K
1-year change:
14.95%
Market cap:
$4.2B
Revenue:
$1.1B
EPS (TTM):
$4.27
Analysts' Opinion
-
Consensus RatingPrestige Consumer Healthcare has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $89.14, Prestige Consumer Healthcare has an estimated upside of 5.67% from its current price of $84.36.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $75.00 representing 11.1% downside risk from its current price of $84.36.
Fair Value
-
According to the consensus of 7 analysts, Prestige Consumer Healthcare has 5.67% upside to fair value with a price target of $89.14 per share.
PBH vs. S&P 500
-
Over the past 5 trading days, Prestige Consumer Healthcare has overperformed the S&P 500 by 1.42% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Prestige Consumer Healthcare does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Prestige Consumer Healthcare has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Prestige Consumer Healthcare reported revenues of $290.3M.
Earnings Growth
-
Prestige Consumer Healthcare has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Prestige Consumer Healthcare reported earnings per share of $1.22.
Enterprise value:
5.1B
EV / Invested capital:
1.84x
Price / LTM sales:
3.78x
EV / EBIT:
15.53x
EV / Revenue:
4.58x
PEG ratio (5yr expected):
--
EV / Free cash flow:
20.59x
Price / Operating cash flow:
17.01x
Enterprise value / EBITDA:
14.20x
Gross Profit (TTM):
$616.3M
Return On Assets:
6.44%
Net Income Margin (TTM):
19.13%
Return On Equity:
12.65%
Return On Invested Capital:
7.69%
Operating Margin:
31.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.1B | $1.1B | $1.1B | $282.7M | $290.3M | |
| Gross Profit | $620.4M | $626.4M | $616.3M | $157.9M | $161M | |
| Operating Income | $337.1M | $349.5M | $330.5M | $86.8M | $92M | |
| EBITDA | $366M | $10.8M | $360.4M | $93.8M | $98.5M | |
| Diluted EPS | $4.17 | -$1.64 | $4.27 | $1.06 | $1.22 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $301.2M | $275.3M | $408.8M | $393.8M | $377.2M | |
| Total Assets | $3.5B | $3.7B | $3.7B | $3.3B | $3.3B | |
| Current Liabilities | $126.2M | $135.1M | $160.2M | $127.4M | $102.5M | |
| Total Liabilities | $2.1B | $2.1B | $2.1B | $1.7B | $1.5B | |
| Total Equity | $1.3B | $1.5B | $1.7B | $1.6B | $1.8B | |
| Total Debt | $1.5B | $1.5B | $1.4B | $1.2B | $992M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $233.9M | $241M | $256.6M | $71.5M | $65.1M | |
| Cash From Investing | -$8.5M | -$11.5M | -$29M | -$4.5M | -$9.8M | |
| Cash From Financing | -$159.5M | -$253.1M | -$239M | -$64.8M | -$53.9M | |
| Free Cash Flow | $225.5M | $232M | $248.7M | $69.5M | $63.5M | |
PBH
Sector
Market Cap
$4.2B
$37.4M
Price % of 52-Week High
93.69%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
2.44%
-0.75%
1-Year Price Total Return
14.95%
-38.36%
Beta (5-Year)
0.457
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$83.91
200-day SMA
Buy
Level
$75.16
Bollinger Bands (100)
Buy
Level
76.3 - 85.16
Chaikin Money Flow
Buy
Level
13M
20-day SMA
Sell
Level
$84.93
Relative Strength Index (RSI14)
Buy
Level
50.81
ADX Line
Buy
Level
16.87
Williams %R
Neutral
Level
-68.7235
50-day SMA
Buy
Level
$81.50
MACD (12, 26)
Buy
Level
0.42
25-day Aroon Oscillator
Sell
Level
-8
On Balance Volume
Neutral
Level
1.5M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.6435)
Buy
CA Score
(Annual)
Level (-0.0304)
Buy
Beneish M-Score
(Annual)
Level (-2.4718)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-1.1102)
Buy
Piotroski F Score
(Annual)
Level (9)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Stock Forecast FAQ
In the current month, PBH has received 4 Buy ratings 3 Hold ratings, and 0 Sell ratings. The PBH average analyst price target in the past 3 months is $89.14.
-
Where Will Prestige Consumer Healthcare Stock Be In 1 Year?
According to analysts, the consensus estimate is that Prestige Consumer Healthcare share price will rise to $89.14 per share over the next 12 months.
-
What Do Analysts Say About Prestige Consumer Healthcare?
Analysts are divided on their view about Prestige Consumer Healthcare share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Prestige Consumer Healthcare is a Sell and believe this share price will drop from its current level to $75.00.
-
What Is Prestige Consumer Healthcare's Price Target?
The price target for Prestige Consumer Healthcare over the next 1-year time period is forecast to be $89.14 according to 7 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is PBH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Prestige Consumer Healthcare is a Buy. 4 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PBH?
You can purchase shares of Prestige Consumer Healthcare via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Prestige Consumer Healthcare shares.
-
What Is The Prestige Consumer Healthcare Share Price Today?
Prestige Consumer Healthcare was last trading at $84.22 per share. This represents the most recent stock quote for Prestige Consumer Healthcare. Yesterday, Prestige Consumer Healthcare closed at $84.36 per share.
-
How To Buy Prestige Consumer Healthcare Stock Online?
In order to purchase Prestige Consumer Healthcare stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
52
RGC alert for Mar 21
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Buy
95
EXOD alert for Mar 21
Exodus Movement [EXOD] is up 1.11% over the past day.
Sell
15
FG alert for Mar 21
F&G Annuities & Life [FG] is down 4.61% over the past day.
